English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Prostate cancer (PCa) is a leading cause of cancer-related deaths. The American Cancer Society expects >198 000 newly diagnosed cases and 31 500 deaths related to PCa in the US in 2001 (1).The indolent clinical course of PCa makes its early detection a challenge. Symptoms typically do not occur until PCa is locally advanced or metastasized, at which time cure is not usually possible. Early detection is therefore mandatory to reduce the mortality of PCa. Prostate-specific antigen (PSA) is a serine protease synthesized in prostatic epithelium. Introduced into clinical use in the late 1980s (2), PSA today is recognized as the most useful tumor marker in urologic oncology and as indispensable for early detection, staging, and monitoring of PCa (3).Digital rectal examination (DRE) alone has a poor sensitivity of 2.2–25% (4)(5) and specificity of 39% (6) in detecting PCa. Measurement of serum PSA concentrations in combination with DRE markedly improves the detection of PCa and increases the lead time for diagnosis (4)(5).This clinical study was designed to demonstrate the clinical utility of the newly developed Roche Diagnostics Elecsys® total PSA Assay on the Roche/Hitachi Elecsys 2010 and 1010 systems. This assay is a quantitative in vitro diagnostic test for detection of total PSA (tPSA) and is indicated for measurement of tPSA in combination with DRE to aid in the diagnosis of PCa.A total of 1121 serum samples for PSA analysis were prospectively taken from men referred for urologic evaluation (mean age, 66 years; range, 50–91 years). DRE was performed by urologists. Symptoms leading to referral were, e.g., voiding dysfunction, lower back pain, or perineal discomfort. No previous PSA values were available, nor had any patient undergone a previous biopsy. No DRE was performed <15 days and no medical …

Clinical Evaluation of the Elecsys Total Prostate-specific Antigen Assay on the Elecsys 1010 and 2010 Systems